CXCL11 and cancer: Furthermore, when the authors treated HUVEC with a CXCL11 siRNA, or treated MDA-MB-231 cells with a siRNA for CXCR3 receptor, they observed a strong inhibition of the ability of the senescent HUVEC to alter the spheroid invasion of cancer cells, demonstrating that CXCL11 can be targeted to hamper the adverse effects of therapy induced-senescent endothelial cells [89].